Probiotics for Mood and Behavioral Disorder Management

Using genetically engineered microorganisms to produce and secrete serotonin (5-HT), tryptamine (TRM), 5-hydroxytryptophan (5-HTP), or melatonin for therapeutic use. The recombinant microorganisms are administered to patients with disorders related to serotonin, tryptamine, 5-HTP, or melatonin deficiencies, such as CNS disorders, GI disorders, hormonal imbalances, metabolic diseases, NAFLD, NASH, and diabetes. The microorganisms express enzymes like tryptophan hydroxylase or decarboxylase to synthesize the needed compounds in the patient's gut.

Source

Using combinations of microorganisms and compounds to modulate the endocannabinoid system for treating conditions like migraine, fibromyalgia, irritable bowel disease, diabetes, PTSD, autism, Parkinson's and others. The method involves administering specific microorganisms and prebiotics that can modulate elements of the endocannabinoid system, along with compounds like cannabinoids that also modulate the system.

Source

Administering combinations of probiotics and drugs that modulate the opioid system to treat conditions associated with opioid system dysregulation. The probiotics and drugs can modulate opioid receptors, endogenous opioids, and opioid synthesis/degradation enzymes to rebalance the opioid system. The specific combinations include microorganisms like Lactobacillus rhamnosus along with compounds like morphine, naloxone, and codeine to treat conditions like pain, addiction, gastrointestinal issues, and autism symptoms.

Source

Fecal microbiota transplantation (FMT) as a treatment for alcohol use disorder (AUD) that modulates cognition, behavior, daily function, short-term alcohol craving and alcohol consumption by changing the microbial composition and function in the FMT recipient. The FMT involves transferring fecal material from a donor with a beneficial microbiota profile associated with reduced alcohol craving to a subject with AUD. The FMT is administered rectally as an enema, suppository or oral capsules. The microbiota in the fecal material populate the subject's gut and alter their microbiome to potentially reduce alcohol craving and consumption. FMT for AUD could be a microbial therapy to help treat alcohol addiction.

Source

Composition of bioconverted black soybean powder produced by fermenting whole soy milk with a specific Bacillus polyfermenticus strain. The bioconversion enhances the functionality of the soybeans by breaking down the proteins into bioactive peptides and amino acids using enzymes from the bacteria. The resulting bioconverted black soybean powder contains low molecular weight functional amino acids and peptides that have increased antioxidant activity and can prevent or improve behavioral disorders.

Source

A nano-armored single cell product for treating Parkinson's disease that encapsulates probiotic bacteria producing gamma-aminobutyric acid (GABA) inside liposomes. The liposome coating protects the bacteria from stomach acid and enzymes during oral ingestion. Once in the intestines, the liposomes break down and release the bacteria to produce GABA that can be absorbed into the bloodstream and cross the blood-brain barrier to potentially alleviate Parkinson's symptoms.

Source

An oral composition containing S-adenosyl methionine (SAMe) and probiotics for treating and preventing mood disorders like anxiety and depression. The composition can be in stable solid forms like orosoluble granulates or tablets. The composition improves patient adherence to therapy by combining the mood regulating SAMe with live probiotics that reach the gut intact.

Source

Using a strain of Lactobacillus plantarum called PS128 to reduce behavioral abnormalities in neurodevelopmental disorders like autism, ADHD, Tourette's, etc. The method involves administering PS128 to individuals aged 7-15 who suffer from these disorders. The PS128 must be given for at least a week to see benefits like reduced anxiety, opposition, hyperactivity, etc.

Source

Administering an oral composition of Lactobacillus fermentum GKF3 to smokers to reduce their tobacco addiction.

Source

Composition for relieving stress using fermented and aged noni and calamansi extract.

Source

Composition and agents containing Lactobacillus paracasei to suppress and improve depression. Lactobacillus paracasei strain KW3110 was found to effectively suppress and improve depression when ingested. The strain can be used in a composition, agent, or method for depression relief.

Source

Probiotic compositions containing specific bacteria for improving symptoms of autism spectrum disorder (ASD) and schizophrenia when administered to individuals with an adult gut microbiota profile. The probiotics are identified from the bacteria Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides vulgatus, and Enterococcus faecalis. Administering these bacteria can improve anxiety, repetitive behavior, and communication in adults with ASD and schizophrenia.

Source

Reducing tobacco addiction in smoking subjects using Lactobacillus fermentum GKF3. The method involves daily oral administration of an effective dosage of the bacterium to smoking subjects. The Lactobacillus fermentum GKF3 can be obtained from China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC 15203.

Source

A sleep-promoting composition including one or more microorganisms that belong to species Bifidobacterium adolescentis and species Lactobacillus plantarum. The composition promotes sleep by increasing sleep amount, improving sleep quality, and reducing sleep onset latency. The microorganisms can be used in foods, beverages, supplements, and drugs to help with sleep.

Source

Probiotic composition for treating rapid eye movement sleep behavior disorder containing specific strains of Bacillus, Bifidobacterium, Lactobacillus, and Enterococcus bacteria. The composition improves symptoms of rapid eye movement sleep behavior disorder (RBD) and Parkinson's disease (PD), and can reduce the levodopa dosage needed for PD. It has better efficacy and stability compared to other probiotic formulations.

Source

Recombinant microbial cells that produce L-DOPA to provide sustained release of the compound for treatment of Parkinson's disease and related disorders. The cells, such as probiotic bacteria, are engineered to produce L-DOPA and when administered to patients, colonize the gut and continuously provide the dopamine precursor. This avoids the pulsatile dosing of traditional L-DOPA tablets that can induce dyskinesia.

Source

Compositions for promoting the neurological health, psychological health or brain health of an individual to treat behavioral or neurological disorders. The compositions contain specific bacterial metabolites, such as phenyl sulfate, pyrocatechol sulfate, 3-(3-sulfooxyphenyl)propanoic acid, and indoxyl sulfate, or bacteria that produce these metabolites. The bacterial metabolites can be formulated as dietary supplements, probiotics or pharmaceuticals to restore normal brain function and behavior in conditions like anxiety disorders.

Source

Probiotic formulation to reduce stress and anxiety. The formulation contains a consortium of probiotic microbes, including Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve and Bifidobacterium infantis. The probiotic microbes produce neurotransmitters like GABA when metabolizing glutamine in the gut. This inhibitory neurotransmitter helps to reduce stress and anxiety when it reaches the brain.

Source

A lactic acid bacterium, Lactobacillus delbrueckii subspecies lactis, or a lactic acid bacterium-derived ingredient therefrom, as an active ingredient for preventing, treating or ameliorating stress disorders. This bacterial ingredient can be formulated into a composition with additional ingredients like water-soluble dietary fibers to enhance the effect.

Source

Using microbiome analysis to diagnose and treat autism spectrum disorder (ASD) by characterizing the gut bacteria of ASD patients versus neurotypical individuals. The analysis found significant differences in microbial diversity and composition between the two groups. Low levels of Prevotella, Coprococcus, Prevotellaceae, and Veillonellaceae bacteria were associated with ASD.

Source